Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Molecular mechanisms driving the in vivo development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR Pseudomonas aeruginosa infections

  • Arca-Suárez, Jorge
  • Lasarte-Monterrubio, Cristina
  • Rodiño-Janeiro, Bruno Kotska
  • Cabot, Gabriel
  • Vázquez-Ucha, Juan Carlos
  • Rodríguez-Iglesias, Manuel
  • Galán-Sánchez, Fátima
  • Beceiro Casas, Alejandro
  • González-Bello, Concepción
  • Oliver, Antonio
  • Bou, Germán
[Abstract] Background: The development of resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of Pseudomonas aeruginosa infections is concerning. Objectives: Characterization of the mechanisms leading to the development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR P. aeruginosa infections. Methods: Four paired ceftolozane/tazobactam- and ceftazidime/avibactam-susceptible/resistant isolates were evaluated. MICs were determined by broth microdilution. STs, resistance mechanisms and genetic context of β-lactamases were determined by genotypic methods, including WGS. The OXA-10 variants were cloned in PAO1 to assess their impact on resistance. Models for the OXA-10 derivatives were constructed to evaluate the structural impact of the amino acid changes. Results: The same XDR ST253 P. aeruginosa clone was detected in all four cases evaluated. All initial isolates showed OprD deficiency, produced an OXA-10 enzyme and were susceptible to ceftazidime, ceftolozane/tazobactam, ceftazidime/avibactam and colistin. During treatment, the isolates developed resistance to all cephalosporins. Comparative genomic analysis revealed that the evolved resistant isolates had acquired mutations in the OXA-10 enzyme: OXA-14 (Gly157Asp), OXA-794 (Trp154Cys), OXA-795 (ΔPhe153-Trp154) and OXA-824 (Asn143Lys). PAO1 transformants producing the evolved OXA-10 derivatives showed enhanced ceftolozane/tazobactam and ceftazidime/avibactam resistance but decreased meropenem MICs in a PAO1 background. Imipenem/relebactam retained activity against all strains. Homology models revealed important changes in regions adjacent to the active site of the OXA-10 enzyme. The blaOXA-10 gene was plasmid borne and acquired due to transposition of Tn6746 in the pHUPM plasmid scaffold. Conclusions: Modification of OXA-10 is a mechanism involved in the in vivo acquisition of resistance to cephalosporin/β-lactamase inhibitor combinations in P. aeruginosa., This work was supported by MSD through the Investigator Initiated Studies Program, which provided financial support and relebactam. This work was also supported by the Ministerio de Economía y Competitividad of Spain, Instituto de Salud Carlos III (ISCIII), through grants PI15/00860 and PI18/00501 to G.B., PI18/00076 to A.O. and P14/00059 and P17/01482 to A.B. Support was also provided by: Planes Nacionales de I + D+i 2013-2016 and ISCIII, Subdireción General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/006) co-financed by the European Development Regional Fund ‘A way to achieve Europe’; and the operative Intelligent Growth Program 2014-2020. C.G.-B. acknowledges financial support from the Spanish Ministry of Economy and Competiveness (SAF2016-75638-R), the Xunta de Galicia [ED431B 2018/04 and Centro singular de investigación de Galicia accreditation 2019-2022 (ED431G 2019/03)] and the European Regional Development Fund (ERDF). J.A.-S. was financially supported by the Fundación Profesor Novoa Santos through a Post-Especialización Grant (2019) and by the Rio Hortega Program (ISCIII, CM19/00219). J.C.V.-U. was financially supported by the pFIS Program (ISCIII, PI17/01482). C.L.-M. was financially supported by an IN606A-2019/029 Grant (Xunta de Galicia).
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Molecular and biochemical insights into the in vivo evolution of AmpC-mediated resistance to ceftolozane/tazobactam during treatment of an MDR Pseudomonas aeruginosa infection

  • Arca-Suárez, Jorge
  • Vázquez-Ucha, Juan Carlos
  • Fraile-Ribot, Pablo Arturo
  • Lence, Emilio
  • Cabot, Gabriel
  • Martínez Guitián, Marta
  • Lasarte-Monterrubio, Cristina
  • Rodríguez-Iglesias, Manuel
  • Beceiro Casas, Alejandro
  • González-Bello, Concepción
  • Galán-Sánchez, Fátima
  • Oliver, Antonio
  • Bou, Germán
[Abstract] Background: Pseudomonas aeruginosa may develop resistance to novel cephalosporin/β-lactamase inhibitor combinations during therapy through the acquisition of structural mutations in AmpC. Objectives: To describe the molecular and biochemical mechanisms involved in the development of resistance to ceftolozane/tazobactam in vivo through the selection and overproduction of a novel AmpC variant, designated PDC-315. Methods: Paired susceptible/resistant isolates obtained before and during ceftolozane/tazobactam treatment were evaluated. MICs were determined by broth microdilution. Mutational changes were investigated through WGS. Characterization of the novel PDC-315 variant was performed through genotypic and biochemical studies. The effects at the molecular level of the Asp245Asn change were analysed by molecular dynamics simulations using Amber. Results: WGS identified mutations leading to modification (Asp245Asn) and overproduction of AmpC. Susceptibility testing revealed that PAOΔC producing PDC-315 displayed increased MICs of ceftolozane/tazobactam, decreased MICs of piperacillin/tazobactam and imipenem and similar susceptibility to ceftazidime/avibactam compared with WT PDCs. The catalytic efficiency of PDC-315 for ceftolozane was 10-fold higher in relation to the WT PDCs, but 3.5- and 5-fold lower for piperacillin and imipenem. IC50 values indicated strong inhibition of PDC-315 by avibactam, but resistance to cloxacillin inhibition. Analysis at the atomic level explained that the particular behaviour of PDC-315 is linked to conformational changes in the H10 helix that favour the approximation of key catalytic residues to the active site. Conclusions: We deciphered the precise mechanisms that led to the in vivo emergence of resistance to ceftolozane/tazobactam in P. aeruginosa through the selection of the novel PDC-315 enzyme. The characterization of this new variant expands our knowledge about AmpC-mediated resistance to cephalosporin/β-lactamase inhibitors in P. aeruginosa., This work was supported by the Ministerio de Economía y Competitividad of Spain, Instituto de Salud Carlos III, through grants PI15/00860 and PI18/00501 to G.B., PI18/00076 to A.O., and P14/00059 and P17/01482 to A.B. Support was also provided by Planes Nacionales de I + D+i 2013–2016 and ISCIII, Subdireción General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/006) co-financed by the European Development Regional Fund ‘A way to achieve Europe’; and the operative Intelligent Growth program 2014–2020. C.G-B. acknowledges financial support from the Spanish Ministry of Economy and Competiveness (SAF2016-75638-R, C.G-B.), the Xunta de Galicia [ED431B 2018/04 and Centro singular de investigación de Galicia accreditation 2019-2022 (ED431G 2019/03)], and the European Regional Development Fund (ERDF). E.L. thanks the Xunta de Galicia for his postdoctoral fellowship. J.A-S. was financially supported by the Fundación Profesor Novoa Santos through a Post-especialización Grant (2019) and by the Rio Hortega program (ISCIII, CM19/00219). J.C.V-U. was financially supported by the pFIS program (ISCIII, PI17/01482). M.M-G. was financially supported by a Clara Roy grant (SEIMC) and C.L-M. by IN606A-2019/029.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Challenging antimicrobial susceptibility and evolution of resistance (oxa-681) during treatment of a long-term nosocomial infection caused by a pseudomonas aeruginosa ST175 Clone

  • Arca-Suárez, Jorge
  • Fraile-Ribot, Pablo Arturo
  • Vázquez-Ucha, Juan Carlos
  • Cabot, Gabriel
  • Martínez Guitián, Marta
  • Lence, Emilio
  • González-Bello, Concepción
  • Beceiro Casas, Alejandro
  • Rodríguez-Iglesias, Manuel
  • Galán, Fátima
  • Bou, Germán
  • Oliver, Antonio
Case report, [Abstract] Selection of extended-spectrum mutations in narrow-spectrum oxacillinases (e.g., OXA-2 and OXA-10) is an emerging mechanism for development of in vivo resistance to ceftolozane-tazobactam and ceftazidime-avibactam in Pseudomonas aeruginosa Detection of these challenging enzymes therefore seems essential to prevent clinical failure, but the complex phenotypic plasticity exhibited by this species may often lead to their underestimation. The underlying resistance mechanisms of two sequence type 175 (ST175) P. aeruginosa isolates showing multidrug-resistant phenotypes and recovered at early and late stages of a long-term nosocomial infection were evaluated. Whole-genome sequencing (WGS) was used to investigate resistance genomics, whereas molecular and biochemical methods were used for characterization of a novel extended-spectrum OXA-2 variant selected during therapy. The metallo-β-lactamase blaVIM-20 and the narrow-spectrum oxacillinase blaOXA-2 were present in both isolates, although they differed by an inactivating mutation in the mexB subunit, present only in the early isolate, and in a mutation in the blaOXA-2 β-lactamase, present only in the final isolate. The new OXA-2 variant, designated OXA-681, conferred elevated MICs of the novel cephalosporin-β-lactamase inhibitor combinations in a PAO1 background. Compared to OXA-2, kinetic parameters of the OXA-681 enzyme revealed a substantial increase in the hydrolysis of cephalosporins, including ceftolozane. We describe the emergence of the novel variant OXA-681 during treatment of a nosocomial infection caused by a Pseudomonas aeruginosa ST175 high-risk clone. The ability of OXA-681 to confer cross-resistance to ceftolozane-tazobactam and ceftazidime-avibactam together with the complex antimicrobial resistance profiles exhibited by the clinical strains harboring this new enzyme argue for maintaining active surveillance on emerging broad-spectrum resistance in P. aeruginosa., This work was supported by the Ministerio de Economía y Competitividad of Spain, Instituto de Salud Carlos III, through grants PI1800076 to A.O., PI15/00860 and PI18/00501 to G.B., and P14/00059 and P17/01482 to A.B. and through grants from the Spanish Ministry of Economy and Competitiveness (SAF2016-75638-R) and the Xunta de Galicia (ED431G/09) to C.G.-B. This work was also supported by the European Regional Development Fund A Way To Achieve Europe ERDF, through the Spanish Network for Research in Infectious Diseases (RD16/0016). J.C.V.-U. was financially supported by the pFIS program (ISCIII, PI17/01482), and M.M.-G. was financially supported by a Clara Roy grant (SEIMC).
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Therapeutic Efficacy of LN-1-255 in Combination with Imipenem in Severe Infection Caused by Carbapenem-Resistant Acinetobacter baumannii

  • Vázquez-Ucha, Juan Carlos
  • Martínez Guitián, Marta
  • Maneiro Rey, María
  • Conde-Pérez, Kelly
  • Álvarez-Fraga, Laura
  • Torrens Ribot, Gabriel
  • Oliver, Antonio
  • Buynak, John
  • Bonomo, Robert
  • Bou, Germán
  • González-Bello, Concepción
  • Poza, Margarita
  • Beceiro Casas, Alejandro
[Abstract] The carbapenem-hydrolyzing class D β-lactamases (CHDLs) are the main mechanism of carbapenem resistance in Acinetobacter baumannii. CHDLs are not effectively inactivated by clinically available β-lactam-type inhibitors. We have previously described the in vitro efficacy of the inhibitor LN-1-255 in combination with carbapenems. The aim of this study was to compare the efficacy of LN-1-255 with that of imipenem in murine pneumonia using A. baumannii strains carrying their most extended carbapenemases, OXA-23 and OXA-24/40. The blaOXA-23 and blaOXA-24/40 genes were cloned into the carbapenem-susceptible A. baumannii ATCC 17978 strain. Clinical isolates Ab1 and JC12/04, producing the enzymes OXA-23 and OXA-24/40, respectively, were used in the study. Pharmacokinetic (PK) parameters were determined. An experimental pneumonia model was used to evaluate the efficacy of the combined imipenem–LN-1-255 therapy. MICs of imipenem decreased between 32- and 128-fold in the presence of LN-1-255. Intramuscular treatment with imipenem–LN-1-255 (30/50 mg/kg) decreased the bacterial burden by (i) 4 and 1.7 log10 CFU/g lung in the infection with the ATCC 17978-OXA-23 and Ab1 strains, respectively, and by (ii) 2.5 and 4.5 log10 CFU/g lung in the infection produced by the ATCC 17978-OXA-24/40 and the JC12/04 strains, respectively. In all assays, combined therapy offered higher protection against pneumonia than that provided by monotherapy. No toxicity was observed in treated mice. Imipenem treatment combined with LN-1-255 treatment significantly reduced the severity of infection by carbapenem-resistant A. baumannii strains carrying CHDLs. Preclinical assays demonstrated the potential of LN-1-255 and imipenem therapy as a new antibacterial treatment., This work has been funded by projects PI15/00860 to G.B., CP13/00226 to A.B., and P14/00059 and PI17/01482 to M.P. and A.B., all of which were integrated into the National Plan for Scientific Research, Development and Technological Innovation 2013–2016 and funded by the ISCIII–General Subdirection of Assessment and Promotion of the Research-European Regional Development Fund (FEDER) “A way of making Europe,” The study was also funded by project IN607A 2016/22 (Consellería de Cultura, Educación e Ordenación Universitaria) to G.B. This study was also funded by the Spanish Ministry of Economy and Competiveness (SAF2016-75638-R), Xunta de Galicia (Centro Singular de Investigación de Galicia accreditation 2016 to 2019, ED431G/09), and by the European Regional Development Fund (ERDF) to C.G.-B. This work was also supported by Planes Nacionales de I+D+i 2008-2011/2013-2016 and by Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía y Competitividad, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/006), cofinanced by the European Development Regional Fund “A way to achieve Europe” and operative program Intelligent Growth 2014–2020. Also, this study was supported in part by funds from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (USA) under award numbers R01AI063517, R01AI072219, and R01AI100560, by funds and/or facilities provided by the Cleveland Department of Veterans Affairs, the Veterans Affairs Merit Review Program award 1I01BX001974, and by the Geriatric Research Education and Clinical Center VISN 10 to R.A.B. J.D.B. acknowledges support from the National Institutes of Allergy and Infectious Diseases under award number R15AI142699. J.C.V.-U. was financially supported by the Miguel Servet Programme (CP13/00226; ISCIII, Spain) and by Consellería de Cultura, Educación e Ordenación Universitaria (IN607A 2016/22), and M.M.-G. was financially supported by a Clara Roy grant (Spanish Society of Clinical Microbiology and Infectious Diseases [SEIMC])., Xunta de Galicia; IN607A 2016/22, Xunta de Galicia; ED431G/09, Estados Unidos. National Institute of Allergy and Infectious Diseases; R01AI063517, Estados Unidos. National Institute of Allergy and Infectious Diseases; R01AI072219, Estados Unidos. National Institute of Allergy and Infectious Diseases; R01AI100560, Estados Unidos. National Institutes of Allergy and Infectious Diseases; R15AI142699